As people age, age-associated systemic inflammation becomes more prevalent and is closely associated to numerous age-related conditions such as heart disease, diabetes, and neurodegenerative disorders. This inflammation is typically assessed through measurable serum proteins in the blood, including interleukin-6, tumor necrosis factor-alpha, and C-reactive protein.

Researchers have been exploring potential strategies to modulate these markers and improve health outcomes in older adults. One compound gaining significant attention is nicotinamide mononucleotide. NMN serves as a building block to NAD+, a essential molecule for cellular ATP synthesis and DNA maintenance.

Studies in both animal models and early human trials suggest that NMN supplementation may modestly reduce levels of these inflammatory markers. In mouse studies, older mice administered NMN demonstrated notable declines in interleukin-6 and tumor necrosis factor-alpha, compared to placebo groups. These animals also showed better glucose regulation and decreased cellular injury.

In early-phase clinical trials, participants who took NMN daily for several weeks reported clinically relevant decreases in CRP and other inflammation-related proteins. The biological rationale is that NMN helps restore declining NAD+ levels that occur with aging. Restored NAD+ levels activate the activity of NAD+-dependent deacetylases, a group of proteins essential for controlling mitochondrial function and suppressing immune overactivation.

By stimulating these cellular pathways, NMN may moderate the overactive immune response commonly observed in aging. While the results are encouraging, it is crucial to note that the majority of existing research have been small-scale or restricted to animal models. Larger, long-term human trials are required to establish causality click and visit here to determine the optimal dosage and safety profile.

Nonetheless, the emerging evidence suggests that NMN could become a promising therapeutic strategy to help older adults lower systemic inflammatory burden and potentially improve their overall well-being as they age.